Trial Profile
A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs SERCA 2a gene therapy (Primary)
- Indications Cardiomyopathies; Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms CUPID; CUPID-1
- Sponsors Celladon
- 26 Jun 2015 According to a Celladon Corporation media release, company has announced the suspension of its plans for research or development of MYDICAR program.
- 20 Nov 2013 Final results at 3 years presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 26 Sep 2013 The full 3-year long-term follow up results from phase IIa of the CUPID 1 trial (n=39) are published online in Circulation Research, according to a Celladon Corporation media release.